Artelo Biosciences Inc (ARTL)

$1.16 +0.11 (10.48%)
Market Cap 2.45M
Revenue (ttm) 0.00
Net Income (ttm) -12.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 286,600
Avg Vol 1,367,052
Day's Range N/A - N/A
Shares Out 2.33M
Stochastic %K 91%
Beta -0.11
Analysts Hold
Price Target $18.00

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 925 7049
Address:
505 Lomas Santa Fe, Suite 160, Solana Beach, United States
Adubstradesmini
Adubstradesmini Jul. 14 at 9:19 PM
$ARTL
0 · Reply
ya33
ya33 Jul. 14 at 7:55 PM
$ARTL go....
0 · Reply
NYSE_TRADERS
NYSE_TRADERS Jul. 14 at 7:40 AM
$ARTL The whole market what fraud this company is ! This cheap and insignificant PR news will not catch anyone attention anymore . This company is garbage . For 15 year they cheat investors and no product created !
0 · Reply
focafoca99
focafoca99 Jul. 13 at 3:04 PM
$ARTL demonstrated promising nonclinical results showing ART27.13 reduced neuropathic pain in a paclitaxel-induced model.
0 · Reply
TurtleTeeTradez
TurtleTeeTradez Jul. 13 at 1:19 PM
$ARTL has been putting out a solid flow of PRs over the past few weeks. Sooner or later, the market will catch up.
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 13 at 1:08 PM
$ARTL
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 13 at 1:07 PM
$ARTL
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 13 at 1:07 PM
$ARTL great news
0 · Reply
MrTicker
MrTicker Jul. 13 at 1:03 PM
$ARTL Artelo Biosciences Reports Preclinical Results For ART27.13 in Cancer-Related Neuropathic Pain; Findings Suggest Broader Utility In Cancer Supportive Care, Building On Interim Findings From CAReS Phase 2 Clinical Study Which Demonstrated Improvements In Body Weight, Lean Body Mass And Activity Levels BENZINGA 8:03 AM ET 7/13/2026
0 · Reply
MrTicker
MrTicker Jul. 13 at 1:03 PM
$ARTL Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy GLOBENEWSWIRE 8:02 AM ET 7/13/2026
0 · Reply
Latest News on ARTL
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Jul 14, 2026, 8:47 AM EDT - 19 hours ago

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Artelo Biosciences announces results from ART27.13 nonclinical studies

2026-07-13T13:10:08.000Z - 1 day ago

Artelo Biosciences announces results from ART27.13 nonclinical studies

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Jul 13, 2026, 9:02 AM EDT - 1 day ago

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Artelo Biosciences Proxy statement: Proxy filing

Jul 2, 2026, 8:00 AM EDT - 12 days ago

Artelo Biosciences Proxy statement: Proxy filing

Artelo Biosciences presents preclinical pain data for ART26.12

2026-07-01T13:40:23.000Z - 13 days ago

Artelo Biosciences presents preclinical pain data for ART26.12

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Jul 1, 2026, 8:42 AM EDT - 13 days ago

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

Jun 30, 2026, 8:57 AM EDT - 14 days ago

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

Jun 29, 2026, 8:45 AM EDT - 15 days ago

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

Artelo Biosciences Proxy statement: Proxy filing

Jun 22, 2026, 8:00 AM EDT - 22 days ago

Artelo Biosciences Proxy statement: Proxy filing

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Jun 10, 2026, 7:38 AM EDT - 4 weeks ago

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Artelo Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 8:00 AM EDT - 5 weeks ago

Artelo Biosciences Proxy statement: Proxy filing

Artelo Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 8:00 AM EDT - 5 weeks ago

Artelo Biosciences Proxy statement: Proxy filing

Artelo Biosciences Slides: Corporate presentation

Jun 5, 2026, 7:00 AM EDT - 5 weeks ago

Artelo Biosciences Slides: Corporate presentation

Artelo Biosciences Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 7 weeks ago

Artelo Biosciences Proxy statement: Proxy filing

Artelo Biosciences Slides: Corporate presentation

May 20, 2026, 7:00 AM EDT - 7 weeks ago

Artelo Biosciences Slides: Corporate presentation

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

May 14, 2026, 4:05 PM EDT - 2 months ago

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

Artelo Biosciences Registration statement: Registration filing

May 14, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Registration statement: Registration filing

Artelo Biosciences Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Artelo Biosciences Quarterly report: Q1 2026

Artelo Biosciences Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Artelo Biosciences Earnings release: Q1 2026

Artelo Biosciences files $75M mixed securities shelf

2026-05-04T20:48:41.000Z - 2 months ago

Artelo Biosciences files $75M mixed securities shelf

Artelo Biosciences Registration statement: Registration filing

May 4, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Registration statement: Registration filing

Artelo Biosciences announces collaboration with ScienceMachine

2026-04-28T13:43:29.000Z - 2 months ago

Artelo Biosciences announces collaboration with ScienceMachine

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

Apr 28, 2026, 8:25 AM EDT - 2 months ago

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

AI

Artelo Biosciences announces publication of article on ART26.12

2026-04-20T12:15:49.000Z - 3 months ago

Artelo Biosciences announces publication of article on ART26.12

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Apr 20, 2026, 7:50 AM EDT - 3 months ago

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Biosciences Slides: Corporate presentation

Apr 15, 2026, 7:00 AM EDT - 3 months ago

Artelo Biosciences Slides: Corporate presentation

Artelo Biosciences files to sell 9.82M shares of common stock for holders

2026-04-07T20:25:22.000Z - 3 months ago

Artelo Biosciences files to sell 9.82M shares of common stock for holders

Artelo Biosciences regains compliance with Nasdaq

2026-04-07T13:09:13.000Z - 3 months ago

Artelo Biosciences regains compliance with Nasdaq

Artelo Biosciences Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Artelo Biosciences Registration statement: Registration filing

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Apr 7, 2026, 7:50 AM EDT - 3 months ago

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 30, 2026, 4:46 PM EDT - 3 months ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

2026-03-30T09:39:29.000Z - 3 months ago

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

LLY NVO

Artelo Biosciences announces $11M private placement priced at-the-market

2026-03-27T14:45:29.000Z - 3 months ago

Artelo Biosciences announces $11M private placement priced at-the-market

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 27, 2026, 10:40 AM EDT - 3 months ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo announces expansion opportunity for ART27.13 in muscle preservation

2026-03-25T20:40:32.000Z - 3 months ago

Artelo announces expansion opportunity for ART27.13 in muscle preservation

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Mar 25, 2026, 4:05 PM EDT - 3 months ago

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Mar 25, 2026, 7:31 AM EDT - 3 months ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Artelo Biosciences files to sell 4.27M shares of common stock for holders

2026-03-24T21:35:16.000Z - 4 months ago

Artelo Biosciences files to sell 4.27M shares of common stock for holders

Artelo Biosciences Registration statement: Registration filing

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Artelo Biosciences Registration statement: Registration filing

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Artelo Biosciences Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Artelo Biosciences Slides: Corporate presentation

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Artelo Biosciences Slides: Corporate presentation

Artelo Biosciences files to sell 1.64M shares of common stock

2026-03-20T21:20:34.000Z - 4 months ago

Artelo Biosciences files to sell 1.64M shares of common stock

Artelo Biosciences Registration statement: Registration filing

Mar 20, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Mar 18, 2026, 10:41 AM EDT - 4 months ago

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

YYGH

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Mar 18, 2026, 8:07 AM EDT - 4 months ago

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Artelo announces third-party fully funded clinical study agreement for ART27.13

2026-03-18T11:45:26.000Z - 4 months ago

Artelo announces third-party fully funded clinical study agreement for ART27.13

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Mar 18, 2026, 7:41 AM EDT - 4 months ago

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Artelo Biosciences Inc trading halted, news pending

2026-03-09T23:50:10.000Z - 4 months ago

Artelo Biosciences Inc trading halted, news pending

Artelo Biosciences announces 3-for-1 reverse stock split

2026-03-06T13:13:39.000Z - 4 months ago

Artelo Biosciences announces 3-for-1 reverse stock split

Artelo Biosciences Announces Reverse Stock Split

Mar 6, 2026, 8:00 AM EST - 4 months ago

Artelo Biosciences Announces Reverse Stock Split

Artelo Biosciences reports FY25 EPS ($12.52)

2026-02-24T13:05:52.000Z - 5 months ago

Artelo Biosciences reports FY25 EPS ($12.52)

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Feb 24, 2026, 8:00 AM EST - 5 months ago

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Artelo Biosciences Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 5 months ago

Artelo Biosciences Earnings release: Q4 2025

Artelo Biosciences Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 5 months ago

Artelo Biosciences Annual report: Q4 2025

Artelo Biosciences Transcript: AGM 2026

Jan 30, 2026, 11:00 AM EST - 5 months ago

Artelo Biosciences Transcript: AGM 2026

Artelo Biosciences Slides: Investor presentation

Jan 8, 2026, 7:00 AM EST - 6 months ago

Artelo Biosciences Slides: Investor presentation

Artelo Biosciences Proxy statement: Proxy Filing

Jan 7, 2026, 7:00 AM EST - 6 months ago

Artelo Biosciences Proxy statement: Proxy Filing

Artelo comments on White House Executive Order expanding CBD research

2025-12-23T14:05:26.000Z - 7 months ago

Artelo comments on White House Executive Order expanding CBD research

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Dec 23, 2025, 9:00 AM EST - 7 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Artelo Biosciences Proxy statement: Proxy filing

Dec 11, 2025, 7:00 AM EST - 7 months ago

Artelo Biosciences Proxy statement: Proxy filing

Artelo Biosciences Registration statement: Registration Filing

Nov 17, 2025, 7:00 AM EST - 8 months ago

Artelo Biosciences Registration statement: Registration Filing

Artelo Biosciences Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 8 months ago

Artelo Biosciences Earnings release: Q3 2025

Artelo Biosciences Quarterly report: Q3 2025

Nov 12, 2025, 4:00 PM EST - 8 months ago

Artelo Biosciences Quarterly report: Q3 2025

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 8 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Nov 4, 2025, 8:30 AM EST - 9 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 27, 2025, 8:00 AM EDT - 9 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 15, 2025, 9:15 AM EDT - 9 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Oct 1, 2025, 4:05 PM EDT - 10 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 10 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 7:15 PM EDT - 10 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 29, 2025, 8:30 AM EDT - 10 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 5, 2025, 4:05 PM EDT - 11 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 11 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 11:33 AM EDT - 11 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Sep 3, 2025, 8:45 AM EDT - 11 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 25, 2025, 7:55 AM EDT - 11 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Artelo Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Artelo Biosciences Earnings release: Q2 2025

Artelo Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Artelo Biosciences Quarterly report: Q2 2025

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Artelo Biosciences Proxy statement: Proxy Filing

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Proxy statement: Proxy Filing

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 4, 2025, 7:30 AM EDT - 1 year ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Aug 1, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Artelo Biosciences Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Proxy statement: Proxy Filing

Artelo Biosciences Registration statement: Registration Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Registration statement: Registration Filing

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 9, 2025, 7:50 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jul 7, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 30, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Jun 2, 2025, 9:00 AM EDT - 1 year ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Artelo Biosciences Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Earnings release: Q1 2025

Artelo Biosciences Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Quarterly report: Q1 2025

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Apr 28, 2025, 8:45 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Artelo Biosciences Earnings release: Q4 2024

Mar 2, 2025, 6:00 PM EST - 1 year ago

Artelo Biosciences Earnings release: Q4 2024

Artelo Biosciences Annual report: Q4 2024

Mar 2, 2025, 6:00 PM EST - 1 year ago

Artelo Biosciences Annual report: Q4 2024

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 14, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Feb 11, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Jan 13, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Adubstradesmini
Adubstradesmini Jul. 14 at 9:19 PM
$ARTL
0 · Reply
ya33
ya33 Jul. 14 at 7:55 PM
$ARTL go....
0 · Reply
NYSE_TRADERS
NYSE_TRADERS Jul. 14 at 7:40 AM
$ARTL The whole market what fraud this company is ! This cheap and insignificant PR news will not catch anyone attention anymore . This company is garbage . For 15 year they cheat investors and no product created !
0 · Reply
focafoca99
focafoca99 Jul. 13 at 3:04 PM
$ARTL demonstrated promising nonclinical results showing ART27.13 reduced neuropathic pain in a paclitaxel-induced model.
0 · Reply
TurtleTeeTradez
TurtleTeeTradez Jul. 13 at 1:19 PM
$ARTL has been putting out a solid flow of PRs over the past few weeks. Sooner or later, the market will catch up.
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 13 at 1:08 PM
$ARTL
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 13 at 1:07 PM
$ARTL
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 13 at 1:07 PM
$ARTL great news
0 · Reply
MrTicker
MrTicker Jul. 13 at 1:03 PM
$ARTL Artelo Biosciences Reports Preclinical Results For ART27.13 in Cancer-Related Neuropathic Pain; Findings Suggest Broader Utility In Cancer Supportive Care, Building On Interim Findings From CAReS Phase 2 Clinical Study Which Demonstrated Improvements In Body Weight, Lean Body Mass And Activity Levels BENZINGA 8:03 AM ET 7/13/2026
0 · Reply
MrTicker
MrTicker Jul. 13 at 1:03 PM
$ARTL Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy GLOBENEWSWIRE 8:02 AM ET 7/13/2026
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 13 at 1:02 PM
$ARTL Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
0 · Reply
sarah92
sarah92 Jul. 12 at 2:15 PM
$ARTL Artelo focuses on the endocannabinoid system and lipid-signaling pathways, areas with significant unmet medical need and relatively few approved therapies--
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 10 at 2:50 PM
$ARTL $HOOD When robinhood warns you it’s the best time to buy a stock
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 10 at 2:32 PM
$ARTL we got motion $SNDK $GRRR $SPY
0 · Reply
AlanaBanana
AlanaBanana Jul. 10 at 2:30 PM
$ARTL she’s starting to perk up- perhaps it will run soon
0 · Reply
NYSE_TRADERS
NYSE_TRADERS Jul. 9 at 6:40 PM
$ARTL Did you see how to they not allow to close bellow 1$ ? This is what I am talking about. This stock is manipulted and what is coming next ...massive kump to 4-6 $ at least ...and then Dilution will start ...when ? After the vote pass on July 18 ! HERE WILL HAVE MASSIVE PUMP over the next days.... Just vote to pass !
1 · Reply
ya33
ya33 Jul. 9 at 4:02 PM
$ARTL
0 · Reply
NYSE_TRADERS
NYSE_TRADERS Jul. 9 at 2:41 PM
$ARTL is playing with your nerves and patience. I want to see them to close bellow 1$ . The successfully manipulate the share price . They are shaking the tree before the big jump !
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 8 at 7:22 PM
$ARTL news by September or early release will send us to 7$
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 8 at 7:21 PM
$ARTL
0 · Reply
NYSE_TRADERS
NYSE_TRADERS Jul. 8 at 7:09 PM
$ARTL the question is … will this fraud close bellow 1$ ? I do not think so !!! It is well manipulated. This is the last shaking before the big jump !
1 · Reply
ya33
ya33 Jul. 8 at 5:24 PM
$ARTL
0 · Reply